Dragonfly Therapeutics, Inc.’s Post

New data from our study in people with KRAS G12C-mutant advanced solid tumors, including in #NonSmallCellLungCancer (NSCLC), will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.    Learn more about the results: https://e.lilly/3V892g9 #ASCO24  

CLINICAL SIGNIFICANCE OF NRF2 AND KEAP1 EXPRESSIONS IN NON SMALL CELL LUNG CARCINOMA, Poster Presentation, 1st International Basic Oncology Congress, (02 June 2022, 04 June 2022) 

Oral estrogen receptor PROTAC® vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4/6 or PI3K/mTOR pathway inhibitors in preclinical ER+ breast cancer models https://lnkd.in/gQ-QaNY3

Are combination therapies in oncology the future of CAR T-cell therapy for solid tumors? Research has shown that combinatorial approaches with CAR T-cell therapy can overcome heterogeneity in solid tumors. Read our scientific spotlight to learn more about the benefits of combination therapies and how we can support your next discovery oncology program. Learn more:

Are combination therapies in oncology the future of CAR T-cell therapy for solid tumors? Research has shown that combinatorial approaches with CAR T-cell therapy can overcome heterogeneity in solid tumors. Read our scientific spotlight to learn more about the benefits of combination therapies and how we can support your next discovery oncology program. Learn more:

Are combination therapies in oncology the future of CAR T-cell therapy for solid tumors? Research has shown that combinatorial approaches with CAR T-cell therapy can overcome heterogeneity in solid tumors. Read our scientific spotlight to learn more about the benefits of combination therapies and how we can support your next discovery oncology program. Learn more:

Are combination therapies in oncology the future of CAR T-cell therapy for solid tumors? Research has shown that combinatorial approaches with CAR T-cell therapy can overcome heterogeneity in solid tumors. Read our scientific spotlight to learn more about the benefits of combination therapies and how we can support your next discovery oncology program. Learn more:

Are combination therapies in oncology the future of CAR T-cell therapy for solid tumors? Research has shown that combinatorial approaches with CAR T-cell therapy can overcome heterogeneity in solid tumors. Read our scientific spotlight to learn more about the benefits of combination therapies and how we can support your next discovery oncology program. Learn more:

Are combination therapies in oncology the future of CAR T-cell therapy for solid tumors? Research has shown that combinatorial approaches with CAR T-cell therapy can overcome heterogeneity in solid tumors. Read our scientific spotlight to learn more about the benefits of combination therapies and how we can support your next discovery oncology program. Learn more:

Are combination therapies in oncology the future of CAR T-cell therapy for solid tumors? Research has shown that combinatorial approaches with CAR T-cell therapy can overcome heterogeneity in solid tumors. Read our scientific spotlight to learn more about the benefits of combination therapies and how we can support your next discovery oncology program. Learn more: